









市場行情
/
股票
/
nasdaq-gpcr
/

Structure Therapeutics Inc

GPCR

64.940USD

+2.490+3.99%

收盤 12/19, 16:00（美東）報價延遲15分鐘

3.94B總市值

虧損本益比TTM



Structure Therapeutics Inc

64.940

+2.490+3.99%

概覽公司財務分析

概覽

公司

財務

分析

關於 Structure Therapeutics Inc 公司

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Structure Therapeutics Inc簡介



公司代碼GPCR

公司名稱Structure Therapeutics Inc

上市日期Feb 03, 2023

CEOStevens (Raymond)

員工數量163

證券類型Depository Receipt

年結日Feb 03

公司地址601 Gateway Blvd Suite 900

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94080

電話16504571978

網址https://structuretx.com/

公司代碼GPCR

上市日期Feb 03, 2023

CEOStevens (Raymond)

Structure Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Xichen Lin, Ph.D.

Chief Scientific Officer

49.23K

+885.53%

Mr. Daniel G. Welch

Independent Chairman of the Board

41.17K

Ms. Yingli Ma

Chief Technology Officer

27.34K

+271.74%

Mr. Angus C. Russell

Independent Director

Ms. Sharon Tetlow

Independent Director

Mr. Jun Yoon

Chief Financial Officer, Co-Founder

Dr. Joanne Waldstreicher, M.D.

Independent Director

Mr. Eric L. Dobmeier, J.D.

Independent Director

Dr. Blai Coll, M.D., Ph.D.

Chief Medical Officer

Dr. Raymond Stevens, Ph.D.

Chief Executive Officer, Co-Founder, Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Xichen Lin, Ph.D.

Chief Scientific Officer

49.23K

+885.53%

Mr. Daniel G. Welch

Independent Chairman of the Board

41.17K

Ms. Yingli Ma

Chief Technology Officer

27.34K

+271.74%

Mr. Angus C. Russell

Independent Director

Ms. Sharon Tetlow

Independent Director

Mr. Jun Yoon

Chief Financial Officer, Co-Founder

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Wellington Management Company, LLP

9.95%

Avoro Capital Advisors LLC

7.46%

Janus Henderson Investors

6.43%

Fidelity Management & Research Company LLC

6.20%

Deep Track Capital LP

6.10%

其他

63.86%

持股股東

佔比

Wellington Management Company, LLP

9.95%

Avoro Capital Advisors LLC

7.46%

Janus Henderson Investors

6.43%

Fidelity Management & Research Company LLC

6.20%

Deep Track Capital LP

6.10%

其他

63.86%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

31.99%

Hedge Fund

25.69%

Investment Advisor

20.19%

Venture Capital

4.37%

Individual Investor

2.51%

Research Firm

1.66%

Private Equity

1.65%

Bank and Trust

0.23%

Pension Fund

0.03%

其他

11.68%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

395

54.88M

90.49%

-15.39M

2025Q2

379

59.75M

103.74%

-16.58M

2025Q1

381

62.21M

108.14%

-12.86M

2024Q4

357

66.09M

115.26%

-5.81M

2024Q3

330

65.93M

115.14%

-2.45M

2024Q2

298

63.40M

110.86%

+11.42M

2024Q1

239

45.01M

96.54%

-1.29M

2023Q4

210

43.42M

93.57%

+9.41M

2023Q3

125

33.38M

93.24%

+15.44M

2023Q2

17.69M

49.41%

+2.82M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Wellington Management Company, LLP

6.88M

11.94%

-915.41K

-11.75%

Jun 30, 2025

Janus Henderson Investors

4.57M

7.94%

+217.81K

+5.00%

Jun 30, 2025

Fidelity Management & Research Company LLC

4.73M

8.21%

-1.07M

-18.47%

Jun 30, 2025

Deep Track Capital LP

5.13M

8.91%

+1.03M

+25.22%

Jun 30, 2025

BVF Partners L.P.

1.66M

2.89%

-109.30K

-6.17%

Aug 11, 2025

Baker Bros. Advisors LP

2.51M

4.36%

+2.15M

+593.86%

Jun 30, 2025

Casdin Capital, LLC

1.23M

2.13%

+525.00K

+75.00%

Jun 30, 2025

RA Capital Management, LP

1.52M

2.63%

Jun 30, 2025

Millennium Management LLC

1.22M

2.12%

+429.90K

+54.41%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Roundhill GLP-1 & Weight Loss ETF

5.49%

TrueShares Technology, AI & Deep Learning ETF

3.59%

WisdomTree BioRevolution Fund

1.7%

Virtus LifeSci Biotech Clinical Trials ETF

1.02%

ALPS Medical Breakthroughs ETF

0.81%

American Century Focused Dynamic Growth ETF

0.37%

ProShares Ultra Nasdaq Biotechnology

0.26%

Invesco Nasdaq Biotechnology ETF

0.2%

SPDR S&P Emerging Markets Small Cap ETF

0.18%

Fidelity Fundamental Small-Mid Cap ETF

0.18%

Roundhill GLP-1 & Weight Loss ETF

佔比5.49%

TrueShares Technology, AI & Deep Learning ETF

佔比3.59%

WisdomTree BioRevolution Fund

佔比1.7%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.02%

ALPS Medical Breakthroughs ETF

佔比0.81%

American Century Focused Dynamic Growth ETF

佔比0.37%

ProShares Ultra Nasdaq Biotechnology

佔比0.26%

Invesco Nasdaq Biotechnology ETF

佔比0.2%

SPDR S&P Emerging Markets Small Cap ETF

佔比0.18%

Fidelity Fundamental Small-Mid Cap ETF

佔比0.18%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Structure Therapeutics Inc的前五大股東是誰？



Structure Therapeutics Inc的前五大股東如下：
Wellington Management Company, LLP
持有股份：6.88M
佔總股份比例：11.94%。
Janus Henderson Investors
持有股份：4.57M
佔總股份比例：7.94%。
Fidelity Management & Research Company LLC
持有股份：4.73M
佔總股份比例：8.21%。
Deep Track Capital LP
持有股份：5.13M
佔總股份比例：8.91%。
BVF Partners L.P.
持有股份：1.66M
佔總股份比例：2.89%。